133
THE PHARMACEUTICAL BUSINESS FIRM

3. HECO U1 - Pharm Business Firm1

Embed Size (px)

Citation preview

Page 1: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 1/133

THE PHARMACEUTICAL

BUSINESS FIRM

Page 2: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 2/133

BUSINESS – organized effort of individuals to

produce and sell the products andservices that satisfy society’s needs. 

- also called company enterprise orfirms.

Page 3: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 3/133

DESCRIBING PHARMACEUTICALBUSINESS FIRM

1. Production Firms

2. Manufacturing Firms

3. Trading Firms

4. Service Firms

Page 4: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 4/133

FORMS OF BUSINESS ORGANIZATIONS

Business Firms are organized into 3distinct Groups

1. The major forms

2. The minor forms

3. The modified corporate form

Page 5: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 5/133

The Major Forms of BusinessOrganization

1. Sole Proprietorship

2. Partnership

3. Corporation

Page 6: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 6/133

-Owned by one person

- Most common in retailing, serviceand agriculture

-This furnishes its own capital(savings or supplied by familymembers.

Financing Pharmaceutical Business Firms

1. Sole Proprietorship

Page 7: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 7/133

1. Ease and low cost of starting2. All profits to the owner

3. The owner is in direct control

4. Tax savings are realized

5. There are minimum legal restrictions

6. Freedom to terminate the business

7. Prompt action in site selection, acquisition or lease

8. One man show

ADVANTAGES OF SOLE PROPRIETORSHIP

Page 8: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 8/133

1. Owners have unlimited liability2. There is lack of continuity

3. Difficulty in raising capital

4. Difficulty in hiring employees

5. High risk for failure

6. The jack-of-all- traits/ limited management skills

7. Predisposed to ill-health and dreaded disease

DISADVANTAGES OF SOLE PROPRIETORSHIP

Page 9: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 9/133

Is an association of two ormore persons who place theirresources together to obtainprofit

Partnership

Page 10: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 10/133

1. General Partner- co owned by 2 or more gen. partnerswho are liable for everything the business does

2. Limited Partner- contributes capital to business buthas no management responsibility or liability beyondthe amount he/she invested in the partnership.

3. Universal Partner- common property of all partners

4. Capitalist Partner- contribution to the business are in

the form of money or currency.5. Industrial Partner- own labor or industry to the

partner

Kinds of Partnership

Page 11: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 11/133

 

6. Silent Partner - limited partner who does notparticipate actively.

7. Secret Partner- anonymous partners

8. Dormant Partner- do not participate in day to dayactivities but contribute to capital/ bear losses or any.

9. Nominal Partner- allows his/her name to be identifiedwith the business. No investment, no interest in thebusiness.

Kinds of Partnership

Page 12: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 12/133

1. Ease of formation

2. Additional sources of capital/ availability of capitaland credit.

3. Combined business skills and knowledge (division

of labor and efficiency in operations)

4. Possible tax advantages (no state and federal tax)

5. Employee incentives

6. Similar benefits as that of sole proprietorship

ADVANTAGES OF A PARTNERSHIP

Page 13: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 13/133

1. Unlimited Liability

2. Divided Authority

3. Lack of Continuity4. Frozen Investment

5. Effect of Management disagreement

DISADVANTAGES OF A

PARTNERSHIP

Page 14: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 14/133

-Is an artificial being, invisible,intangible and existing only incontemplation of the law.--juridicialbeing

-The capital of a corporation is

obtained by the scale of shares ofstock from the members of thecorporation.

CORPORATIONS

Page 15: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 15/133

Page 16: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 16/133

1. Limited Liability2. Specialized management

3. Transferability of ownership

4. Continuous existence

5. Greater ease of raising capital

6. Possible tax advantages

Advantages of Corporation

Page 17: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 17/133

1. Complicated to organize

2. Government controls

3. Charter restrictions

4. Double taxation

5. Impersonality and lack of secrecy

6. Dividends

Disadvantages of Corporation

Page 18: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 18/133

The Minor Forms of Business

Organization1. The joint stock company-capital is divided

into small units permitting a number ofinvestors

2. The joint venture- established for a specificproject and for limited time

3. The business trust- trustee is appointed tomanage the business and its operationthrough a trust relationship

Page 19: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 19/133

The Modified Corporate Form of 

Business Organization

1. Cooperatives- association of individualswhich purpose is to perform business for itsmembers

 a. Credit union cooperative- accepts deposit from

its members and lends money to its members atreasonable rates

b. Producer’s cooperative- mutually assist oneanother in the procurement of raw materials,machinery, equipment and other needs to producegoods/services.

Page 20: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 20/133

The Modified Corporate Form of 

Business Organization 

c. Marketing cooperative-  assist its members in

marketing their products.

d . Consumer’s cooperative- provide its members

with quality goods and services at reasonable price

e. Service cooperative- to make services availableto its members 

Page 21: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 21/133

The Modified Corporate Form of 

Business Organization

2. Mutual companies

a. Mutual savings banks-- firm owned by

depositors

b. Mutual insurance company  – organizationowned by policy holders

Page 22: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 22/133

Forms of BusinessOrganizations

Major

Forms

Minor

Forms

Modified

Corporate

Forms

Sole

proprietorshipCorporate

Joint stock

Company

Partnership

Corporation

Joint

Venture

Business Trust

Mutual

Page 23: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 23/133

The Pharmaceutical HealthCare Industry

QUESTION:

Page 24: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 24/133

QUESTION: 1.Which among the key world

market, has the greatest drugsales?

A. EuropeB. United States

C. CanadaD. Japan

Page 25: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 25/133

THE WORLD DRUG MARKET 

Key World Markets Drug Sales in US$ Billion

1. United states 189.81

2. Canada 9.41

3. United Kingdom 14.58

4. European Markets 82.42

5. Japan 55.69

6. France 20.17

7. Germany 23.99

8. Mexico 6.28

Top 10 pharmaceutical markets in the world in current US$ billion

Page 26: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 26/133

Country  1976  Country  1985  Country  2000 

Value  % world  Value  % world  Value  % world 

USA 7.90 18.4 USA 26.45 28.1 USA 149.5 52.9

Japan 4.02 9.3 Japan 14.04 14.9 Japan 51.5 18.2

Germany 3.41 7.9 Germany 6.00 6.4 France 16.7 5.9

France 2.70 6.3 China 4.70 5.0 Germany 16.2 5.7China 2.60 6.0 France 4.47 4.8 UK 11.1 3.9

Italy 1.90 4.4 Italy 3.67 3.9 Italy 10.9 3.9

Spain 1.32 3.1 UK 2.35 2.5 Spain 7.1 2.5

Brazil 1.21 2.8 India 1.78 1.9 Canada 6.2 2.2

UK 1.03 2.4 Canada 1.69 1.8 Brazil 5.2 1.8

Mexico 0.77 1.8 Brazil 1.41 1.5 Mexico 4.9 1.7

Top 10 26.86 62.4 Top 10 66.56 70.8 Top 10 279.3 98.7

World

sales

43.05 100 World

sales

94.10 100 World

sales

282.5 100

Top 10 pharmaceutical markets in the world, in current US$ billion 

Source: World Drug Situation 1988 and IMS Health, IMS MIDAS Customized Insights (October 2001) The information contained in this study is a guide to sales and not a guide to consumption. 

Page 27: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 27/133

QUESTION: 

2. Which among the therapeuticcategories has the highest amountof sales in the world market?

A. CNSB. Cardiovascular

C. MuscoskeletalD. Respiratory

Page 28: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 28/133

The World Drug Market by TherapeuticCategories (as of 2003)

1. Muscoskeletal 21.6

2. CNS 62.08

3. Cardiovascular 65.594. Alimentary/Metabolism 48.28

5. Respiratory 29.11

6. Genitourinary 18.06

7. Cytostatics 16.10

Page 29: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 29/133

As of 2008

QUESTION:

Page 30: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 30/133

QUESTION: 3. Which among the drugs

with a patent expiry has thehighest amount of sales?

A. NorvascB. Adalat

C. CozaarD. Plavix

Page 31: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 31/133

Drugs with Patent Expiry and Sales Figures

Brand Name 2000 sales in US$

Million

Adalat 1.176

Atacand .293

Cozaar 1.077

Flovent/Flixotide 1.307

Norvasc 3.341

Zestril 1.130

Bl k b t D ith P t t E i d

Page 32: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 32/133

Block buster Drugs with Patent Expiry and

Sales Figures (2010)Brand Name Category 2010-2011 sales in

US$ Billions/ 

millions

Plavix Anticoagulant 6.1 B

Lipitor Anticholesterol 5.3 B

Seroquel Antischizophrenia (antipsychotic) 3.7 B

Actos Diabetes 3.3 B

Enbrel Antirheumatoid arthritis and psoriasis 3.3 B

Singulair Anti asthma and allergies 3.2 B

Levaquin Antibiotic (Pnuemonia) 1.3 BZyprexa Antischizophrenia (antipsychotic) 3.5 B

Concerta Anti ADHD 929 M

Protonix Anti GERD 690 M

Page 33: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 33/133

4. Which among the following is the top 1

leading company listed with top leadingbrands as of 2008?

A. Sanofi- AventisB. RocheC. Astra Zeneca

D. Wyeth

Page 34: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 34/133

Page 35: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 35/133

QUESTION:

5. What are the 4 top selling

brands in the world market?

Page 36: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 36/133

Brand Company Indication Sale in $ B

Lipitor

Norvasc

Pfizer, Inc. Cholesterol

Anti-hypertensive

6.449

3.582

Zocor

Cozaar/Hyzaar

Merck &Co. Hypertension

Hypertension

6.700

1.700

Zestril

Seloken

Astra Zeneca Hypertension

Hypertension

1.097

.722

Pravachol

Avapro

Bristol MyersSquib Co

Cholesterol

Hypertension

2.173

.510

WORLD DRUG MARKET

4 TOP SELLING BRANDS (2003)

T S lli M di i l B d 2006 2008

Page 37: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 37/133

Brands®   Generic Name  Companies  Indications  Sales $ billion

2006 2007 2008 A (P)

Lipitor® Atorvastatin Pfizer, Astellas Cholesterol 12.9 13.5 13.35 (13) 

13.6 13.5 13.65

Plavix® Clopidrogel Bristol Myers Squibb, Sanofi

Aventis

Atherosclerosis 5.55 8.2 9.4 (8.9)

5.8 7.3 8.6

Advair® Fluticasone

Salmetrol

Glaxo Smith Kline Asthma 6.13 7.0 7.65 (7.5)

6.3 7.1 7.7

Nexium® Esomaprazole Astra

Zeneca

Ulcers 5.2 5.2 5.2 (5.2)

6.7 7.2 7.8

Top Selling Medicinal Brands 2006- 2008

Page 38: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 38/133

NCE ®  NME ®  Sales Increase ®  Sales Decline ® 

Lipitor 13.35 Enbrel 7.66 Enbrel 2.46 Protonix 2.71Plavix 9.4 Remicade 6.2 Humira 1.5 Zyrtec 2.1

Advair 7.66 Rituxan 5.48 Remicade 1.2 Fosamax 1.49

Diovan 5.74 Avastin 4.82 Plavix 1.2 Tamiflu 1.29

Nexium 5.2 Herceptin 4.72 Avastin 0.89 Risperdal 1.26

Zyprexa 4.69 Humira 4.5 Diovan 0.74 Aranesp 1.1

Seroquel 4.64 Lovenox 3.99 Erbitux 0.7 Avandia 0.95

Abilify 4.5 Lantus 3.58 Zocyn 0.7 Pravachol 0.92

Singulair 4.33 Aranesp 3.1 Xolair 0.62 Norvasc 0.76

Effexor 3.9 Gardasil 2.8 Seroquel 0.61 Ambien 0.60

Top Ten Medicinal Brands Ranking in 2008 ($ billion)

Page 39: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 39/133

QUESTION: 6. In the Philippine Pharmaceutical

market, which has a greater amount ofsale?

A. Ethical drugsB. Proprietary drugs

Page 40: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 40/133

The Philippine Pharmaceutical Market

Total Pharmaceutical Market2004 = P80.083 Billion

2003 = P70,415 Billion

Ethical and Proprietary

2003 2004

Ethical P50,411 B P57,300 B

Proprietary P 20,004 B P22,783 B

Total P70,415 B P80,083 B

Page 41: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 41/133

QUESTION: 7. Which among the companies has

the greatest amount of sales in in thePhilippine drugstores and hospitals?

A. UnilabB. Glaxo Smith KlineC. Pfizer

D. Wyeth

Page 42: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 42/133

Drugstores and Hospital Sales

TOP 5 COMPANIES

1. United Laboratories 17,331 B

2. Glaxo Smith Kline 8,134 B

3. Pfizer, Inc. 6,421 B

4. Wyeth 5,145 B

5. Astra-Zeneca 3,671 B

Page 43: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 43/133

QUESTION: 8. Which among the therapeutic

classification has the greatest marketshare in the Philippines?

A. VitaminsB. CardiovascularC. Anti-infectives

D. Cough and Colds

Page 44: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 44/133

Therapeutic Classification

Sales in M Market Share1. Anti-infectives 69,600 16.7%

2. Cardiovascular 10,718 15.4%

3. Vitamins-Minerals 7,934 11.4%

4. Somatics 7,447 10.7%

5. Cough-Colds 5,081 13%

Page 45: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 45/133

QUESTION: 9. What is the top 1 ethical product inthe Philippines?

A. NorvascB. VentolinC. Augmentin

D. Plendil

Page 46: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 46/133

Top 10 Ethical Products1. Ventolin Anti-asthma P 1,230 M

2. Norvasc Cardiovascular 730 M

3. Augmentin Anti-infectives 642 M

4. Plendil ER Cardiovascular 558 M

5. Lipitor Cardiovascular 444 M6. Zinnat Anti-infectives 412 M

7. Plavix Cardiovascular 360 M

8. RM-Amoxicillin Anti-infectives 310 M

9. Neobloc Cardiovascular 309 M

10. Diamicron Endocrin 295 M

Page 47: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 47/133

QUESTION: 

10. What is the top 1 brand inPhilippine drugstores and hospitals?

A. BiogesicB. VentolinC. Enervon C

D. Solmux

T 20 B d

Page 48: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 48/133

Top 20 BrandsHospital and Drugstore

1.  Ventolin2. Biogesic

3. Enervon C

4. Ceelin

5. Solmux6. Augmentin

7. Norvasc

8. Alaxan

9. Neozep10. Plendil ER

11. Plavix12. Zinnat

13. Clusivol

14. Revicon

15. Ciprobay16. Diamicron

17. Promil

18. Neobloc

19. Centrum20. Unasyn

Page 49: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 49/133

QUESTION: 

11. What is the top 1 OTC brandPhilippine drugstores and hospitals?

A. BiogesicB. VentolinC. Enervon C

D. Ceelin

T 10 OTC B d

Page 50: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 50/133

Top 10 OTC Brands

1. Ceelin P 1,015 M

2. Enervon C 883 M

3. Alaxan 847 M

4. Solmux 750 M

5. Biogesic 697 M

6. Neozep 642 M

7. Clusivol 467 M

8. Ponstan 432 M

9. Tuseran 378 M

10.Revicon Forte 350 M

QUESTION:

Page 51: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 51/133

QUESTION: 

12. What is the top 1 unbrandedmanufacturers in drugstores andhospitals?

A. PascualB. Ritemed

C. United HomeD. Abbott

Page 52: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 52/133

TOP 10 UNBRANDED MANUFACTURERS

1. RiteMed Phils. 583,469.383 M

2. Pascual laboratories 471,891.551 M

3. Euro-Med Lab 336,841.592 M

4. Bristol Myers 296,472.643 M

5. Abbott Lab 179,010.478 M

6. LVP Phils 153,526.506 M

7. United Home 114,104.099 M

8. Organon 70,063.946 M

9. Rhea 63,307.536 M

10. Pharma Wealth 63,307.536 M

DISTRIBUTION CHANNELS ACCORDING TO SALES

Page 53: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 53/133

DISTRIBUTORS

TRADERS OR SUB-DISTRIBUTORS

DRUGSTORES 85.6% HOSPITAL 11.0% OTHER RETAIL 3.4%

INDEPENDENT27.9%

CHAIN57.7%

PRIVATE8.1%

GOVERNMENT2.9%

INDUSTRIALCLINICS w/o

BED3.0%

GOVERNMENTAGENCIES

0.4%

CLINICS W/BEDS

INDUSTRIALHOSP.

C O N S U M E R

DISTRIBUTION CHANNELS ACCORDING TO SALES

QUESTION:

Page 54: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 54/133

QUESTION: 

13. What is the top 1pharmaceuticalmarket player in thePhilippines today?

A. MercuryB. Med express

C. Multinational companiesD. Watsons

MARKET DRIVERS

Page 55: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 55/133

MARKET DRIVERS

PHILIPPINE PHARMACEUTICAL MARKET

1. Mercury Drug - 500 Branches andfranchises

@ with self service areas

2. Watson – over 100 outlets

@ with pharmacist counseling areas

3. DSAP@ difficulty in implementing S. act

4. Med Express

@ 3 in 1 dru store

Page 56: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 56/133

MARKET DRIVERS

PHILIPPINE PHARMACEUTICAL MARKET

5. CEPPhA ( Continuing education Programfor Pharmacy Assistants)

@ drugstore front liners

6. Drugstore quality awards

@ quality and excellence in the area of…. 

7. Independent drugstore

8. Local and multinational companies

9. Healthcare centers

Page 57: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 57/133

Market Drivers in the hospitalSector

1. Private hospitals

2. Insurance program

3. Public hospitals

4. More Clinical pharmacy practice

5. Health Maintenance Organizations

Page 58: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 58/133

QUESTION: 

What are the 3 sources of funds of

pharmaceutical products in thePhilippines?

Page 59: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 59/133

How Funds Flow In

As with all health care services, fundingfor pharmaceutical products comes fromvariety of sources

1. Patients

2. Employers and private insurance

3. Government

QUESTION

Page 60: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 60/133

QUESTION: 

What is the highest source of funds inthe Pharmaceutical Products ?

A. Out of the pocketB. Private InsuranceC. Phil health

D. Public programs

Page 61: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 61/133

Sources of Funds for Pharmaceutical Products

Total 536 per person, 10% of National

health expenditures

Out-of-pocket 32%

Private insurance 46%

Medicare/Philhealth 17%

Other Insurance 2%Other Public programs 3%

QUESTION:

Page 62: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 62/133

QUESTION: 

The flow of funds in the pharmaceuticalmarket is dominated by ?

A. Branded ManufacturersB. Generic ManufacturersC. Wholesalers

D. Retailers

Flow of Funds in the Pharmaceutical Market

Page 63: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 63/133

Pharmacy

Benefit

Manager

5-15%

Retail Pharmacy

15-25%

Brand name

PharmaceuticalCompanies

70-80%

Wholesale

2-3%

Generic Manufacturers 6%

PATIENTS

Flow of Funds in the Pharmaceutical Market

Page 64: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 64/133

Page 65: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 65/133

Page 66: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 66/133

QUESTION: 

Page 67: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 67/133

Which of the following has the highestallocation of funds in thePharmaceutical Market?

A. Cost of goodsB. Sales and marketing

C. ResearchD. Taxes

Page 68: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 68/133

Uses of Funds For Pharmaceutical Market

1. Cost of goods 30%

2. Research and Development 13%

3. Sales, marketing, administration 31%

4. Taxes 6%

5. Net Income 20%

Research and Development

Page 69: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 69/133

Stages of Drug Testing# of compounds at each stage

Discover – Screen compounds to find a drug 5,000 – 10,000

Preclinical – Laboratory and animal testing 250

IND Investigational New Drug

Stage 1 (20-80 volunteers, safety and dosage) 20

Stage 2 (100-300) patients, test, efficacy, side effects 13

Stage 3 (Large randomized trial of clinical effectiveness) 8

NDA – APPLICATION File New Drug Application 2

FDA approval ( Launch new product) 1

up to 15 years 3-15 - $100M – $150M 

Page 70: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 70/133

QUESTION: 

What is the trend in the drug industryamong patient consumer?

Page 71: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 71/133

EMERGING TRENDS IN THE DRUG INDUSTRY

Patient

Consumer

1. Self diagnosis

Self medication

Self treatment2. Use of OTC drugs,

Herbals, Food

Supplements

3. Minimal purchase

and almost daily

basis4. Hospital confine-

ment, Medical &

Allied services

only in extreme

emergencies

Page 72: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 72/133

Page 73: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 73/133

O h i d d lf di i i

Page 74: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 74/133

On the attitudes towards self-medication practices

Rank Self-medication practices

1 Necessary Remedy

2 Temporary Remedy

3 Safe and Convenient4 Illegal

5 Dangerous

QUESTION:

Page 75: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 75/133

QUESTION: 

What is the most common ailment toself medicate?

A. HeadacheB. coldsC. diarrhea

D. fever

Self-medication practices on common ailments

Page 76: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 76/133

Self medication practices on common ailments

Rank Common Ailments

1 Headache2 Fever

3 Cold

4 Flu

5 Sore Throat

6 Itchiness

7 Skin Rashes

8 Diarrhea

9 Sore Eyes

10 Muscle Pains

11 Pimples

12 Minor Burns

QUESTION: 

Page 77: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 77/133

In the choice of OTC drugs, what isthe number 1 factor that will influenceconsumer to buy?

 A. Doctor’s advise B. Parent’s influence C. Knowledge about the drugD. Advertisement

Profile on the attitudes towards the choice of OTC

Page 78: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 78/133

drugs on the different services of information

RANK Services of Information

1 Doctor’s advice 

2 Advice of parent

3 Knowledge of OTC Drugs

4 Proximity of drugstore

5 Advice of a friend

6 Advice of Drugstore personnel

7 Advertisement

8 Drugstore Display

QUESTION:

Page 79: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 79/133

QUESTION: 

What is the number 1 reason whypeople what to buy OTC?

A. Immediate reliefB. Avoid doctor’s fee C. Save money

Page 80: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 80/133

Intention of Buying

Rank Intentions/Purposes of BuyingOTC drugs

1 To seek immediate relief of minor ailment

2 To save time and efforts going to a doctor’sclinic

3 To save money on prescription drugs

4 To avoid cost of consultation of doctors 

QUESTION: 

Page 81: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 81/133

What is the frequency in buying OTCby an average consumer?

A. Only when necessaryB. One a weekC. Twice a weekD. Once a month

F i B i OTC D

Page 82: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 82/133

Frequency in Buying OTC Drugs

Rank Frequency in Buying OTC

Drugs

1 Only when necessary

2 Twice a month3 Once a month

4 Three times a week 

5 Two times a week 

6 Once a week 

QUESTION: 

Page 83: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 83/133

What is the highest percentage ofbuying an OTC drug?

A. 5%B. Less than 5%C. more than 5%D. more than 10%

P t i B i OTC

Page 84: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 84/133

Percentage in Buying OTC

Rank % in Buying OTC Drugs

1 Small percentage

2 Five percent

3 Ten percent

4 Fifteen percent

5 Over twenty percent

QUESTION:

Page 85: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 85/133

QUESTION: 

What is the most convenient place ?to by an OTCA. drug store

B. Sari-sari storeC. Grocery/ convenient store

Places which are considered convenient or advantageous in

Page 86: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 86/133

aces w c a e co s de ed co ve e t o adva tageous

buying OTC drugs

RANK Places considered convenient or

advantageous in buying OTC drugs

1 Drugstore

2 Sari-sari store

3 Grocery/Supermarket

4 Other Centers/Botica ng Bayan

5 Shell shops/Gasoline stations

QUESTION:

Page 87: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 87/133

QUESTION: 

What is the primary basis of buyingOTC drug?A. Price

B. safetyC. Effectiveness

Primary Basis in Buying OTC Drugs

Page 88: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 88/133

Primary Basis in Buying OTC Drugs

Rank Primary Basis of Buying

OTC Drugs

1 Effectiveness of the product

2 Safety of the product

3 Price of the product

4 Popularity of the product5 Presentation of the product

6 Manufacturer of the product

Page 89: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 89/133

QUESTION: 

What is the trend in the drug industryamong health insurance?

EMERGING TRENDS IN THE DRUG INDUSTRY

Page 90: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 90/133

EMERGING TRENDS IN THE DRUG INDUSTRY

Health Insurance

1. Increasing

Visibility of HMO

2. MD’s and 

Hospital/Private

Entities Owning

HMOs

3. HMO Industrial

Establishments

Partnership

4. HMO Drugstores

Tie-ups

Page 91: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 91/133

QUESTION: 

What is the trend in the drug industryamong community and hospital?

EMERGING TRENDS IN THE DRUG INDUSTRY

Page 92: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 92/133

EMERGING TRENDS IN THE DRUG INDUSTRY

Hospital/Community

Pharmacy

1. Establishing

Franchises to

qualifies entre-

preneurs

2. Hospital Pharmacy

open to general

public

3. 24-hours service in

community

pharmacy

4. One-stop-concept

Wide array of 

assorted goods

THE PHARMACEUTICAL MARKETS

Page 93: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 93/133

Traditional MarketsNon-Traditional Market

DOH/NGO’s 

Drugstores

Hospitals

Industrial clinics

Medical ClinicsDispensing

Physicians

Groceries and

supermarkets

Trading stores andSari-sari stores

Municipalities

Regional Health

Office

Rural Health

centersBarangays & sitios

Botica sa bayan

The Target Consumers for Drug Products

Page 94: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 94/133

A

B

C

D

E

Upper Class

Middle Class

Lower Class

1. Income Level

2. Age Classification

3. Gender

4. Educational Attainment

5. Geographic locations

Flow of Rx in the Hospital OPD

Page 95: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 95/133

Out-Patients

DRUGSTORES

Rx generated from

Residents MDs/ 

Consultants

Buys Rx

Out-Patient Department

(OPD) Hospitals

ow o t e osp ta O

Flow of Rx in Hospital IPD

Page 96: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 96/133

In-Patient Department

(IPD) Hospitals

In-Patient

(Confined in Hospitals)

Hospital Pharmacy

Rx generated from

Residents MDs/ 

Consultants

Rx In Patient’s Chart 

Served by nurses

Emergency Rooms (ER)

Page 97: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 97/133

Out-Patient In-Patient

Emergency Rooms

(ER)

Hospitals

DrugstoresEmergency Rooms

(ER)

Hospitals

g y ( )

HOSPITALS

FLOW OF Rx IN HOSPITAL ERs

Rx bought/served

Rx served

Rx generated from, Residents MDs/Consultants

Page 98: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 98/133

QUESTION: 

What are the different models in

channeling drugs from manufacturersto end users?

Channel 1

Page 99: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 99/133

Channel 1

Consists of a drugmanufacturer selling

directly to the DOH or

government health units and

hospitals who will in turnmake the medicinesavailable to the end-users

practically for free. A local

drug trader may serve as the

intermediary level in behalf of the drug manufacturer in

transacting business with

DOH.

Drug Manufacturer

Department of HealthGov’t. Health Units 

Gov’t. Hospitals 

End Users

LocalDrug

Trader

Channel 2

Page 100: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 100/133

Contains 2 middlemen level.A sales representative of a

drug manufacturer selling to

dispensing physicians who in

turn sells the medicines tothe patients (end-users)charging the latter

consultation fees and

medicines given

Drug Manufacturer

Sales reps

Dispensing

Physicians

END USERS

Channel 3

Page 101: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 101/133

Channel 3

Contains only 1

middlemen level, either

an independent

distributor or retailer,who in turn sells the

drug products to end-

user

Drug Manufacturer

Independent

Distributors

END USERS

Retailers

Channel 4

Page 102: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 102/133

Channel 4

Contains 2 middlemen

level, namely the

wholesaler and retailer

drugstore outlets whoin turn sells to the end-

users. In some

companies, 3

middlemen level when

it’s their salesman that

facilitates the

transactions.

Drug Manufacturer/ 

Distributors

Wholesaler

Retailer

END USERS

Channel 5

Page 103: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 103/133

Channel 5

Contains 3 middlemen

level, reflecting jobbers

who sells to the smaller

retailers generally arenot served by the large

wholesaler drugstores

Drug Manufacturers/ 

Distributions

Wholesaler

End Users

JOBBERS

Retailers

Page 104: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 104/133

QUESTION: 

What is the flow chart distribution ofdrugs of Mercury drug?

Drug ManufacturerFLOWCHART

DISTRIBUTION

Page 105: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 105/133

Independent

Distributors

Company

Warehouse

Branch operations Franchise Operations

Mercury Drug Corp.

Traditional Outlets Traditional Outlets

Non-Traditional Non-TraditionalEnd Users

DISTRIBUTION

Page 106: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 106/133

QUESTION: 

What is the flow chart distribution ofdrugs of unilab?

UNILAB United Lab Distribution

Page 107: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 107/133

UNILAB

Manufacturer

GMA

Warehouse

Provincial

Warehouse

• Drugstores

• Hospitals

• Industrial Clinics

• Non-traditional Outlets• Dispensing Physicians• Department of Health

END USERS

Flow Chart

Page 108: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 108/133

QUESTION: 

What is the common flow chartdistribution of drugs of ?

Drug Manufacturer

Pharmaceutical

Company Distribution

Page 109: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 109/133

National Distributor

Private

Institution

Dispensing

Physicians

Government

Distributors

Wholesale/Retailer

(drugstores)

Government

Agencies

Pure Retailers(drugstores)

END USERS

Flow Chart

Page 110: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 110/133

BUSINESS CYCLES ANDINFLATION

PHASES OF THE BUSINESS

Page 111: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 111/133

PHASES OF THE BUSINESS

CYCLE

1. The prosperity phase

2. The crisis (or contraction or recession)

phase

3. The depression phase

4. The recovery (or expansion) phase 

Characteristics of Prosperity

Page 112: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 112/133

Characteristics of ProsperityPhase

High prices and great

business activity

Large profits for

business firms Production is at full

capacity

Increasing demand for

many commodities Increasing demand for

labor

Increasing volume of 

sales

Increasing volume of 

credit extensions bylenders

Large demand for credit

Rising interest rates

THE PROSPERITY PHASE

Page 113: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 113/133

Great

Business

Activity

Business

Firms

Great

Demand

Raw MaterialsAnd other

Commodities

LABOR LANDCapital

Resulting to

Resulting to

• Higher outputs

• Higher sales

• Higher profits

• Higher Wages

• Higher Rent

• Higher Interest

Rate

• Higher Prices of Materials

and

Supplies

Page 114: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 114/133

Crisis or Recession Phase

The demand forgoods decreases

The margin of profits

gradually shrinks The volume of sales

decreases

Trading slows down

The production of goods is reduced

The demand for labor,capital, and land decreases

Prices go down

The ability of business firms

to meet their financialobligations is impaired

Unemployment begins to

bother labor

No further extensions of 

credit or renewals of old loansare made by banks

THE CRISIS OR RECESSION PHASE

Page 115: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 115/133

Reduced

Business

Activity

Business

Firms

Reduced

Demand

LABORRaw Materials

And otherCommodities

Capital LAND

Resulting to

Resulting to• decreasing outputs sales,

and profits

• decreasing wages,

rent, interest rates,

prices of raw materials

and supplies

D i Ph

Page 116: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 116/133

Depression Phase

Many businesseshave ceasedoperations

Profits are minimal,if it is still possible tomake some

Banks have plenty of 

idle funds Banks are gradually

reduce interest rates

Credits starts to become

available

Unemployment is at its

highest level Many unemployed

persons are willing to

work at lower wages

The prices of rawmaterials and supplies

are low

THE DEPRESSION PHASE

Page 117: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 117/133

Greatly ReducedBusiness

Activity

Reduced #Of Firms

Still Operating

LABORRaw Materials

And otherCommodities

Capital LAND

Resulting to

Resulting to

Very Low

Demand

• Minimal

output, sales, and

profit

• low wages, rent,

interest rates

• low prices of raw

materials and

supplies

R Ph

Page 118: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 118/133

Recovery Phase

As the supply of 

commodities in the market

gets exhausted, demand for

these begin to be felt

Optimism among

businessmen slowly

develops, prodding them to

increase business activity

The demand for laborincreases, resulting to a

decrease in unemployment

The purchasing power of the people rises

The low rates of interestwill attract businessborrowings

Prices slowly rise

There is an increase inproduction output

Idle plans are used andplans for construction of new ones are considered

Page 119: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 119/133

The Business Cycle

Page 120: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 120/133

RE

A

L

G

N

P

TIME

Prosperity

DepressionDepression

Prosperity

Control Of Business Cycles

Page 121: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 121/133

1. The stabilization of business

2. Control of credit

3. Control of public works

4. Business forecasting5. Monetary readjustment

6. Payment of high wages

7. Economic planning

Basic Terms Related To Inflation

Page 122: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 122/133

1. Price level2. Market basket

3. Price index4. Inflation

5. Deflation

Types of inflation

Page 123: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 123/133

Types of inflation

1. Cost-push inflation – is one characterized bycontinual decreased in the aggregate supply,

resulting to increase in the cost of production

2. Demand-pull inflation – is one caused by

increases in aggregate demand

3. Inertial inflation –  is that “steady inflation that

occurs when inflation is expected to persist and

the ongoing rate of inflation is built intocontracts and people’s expectations” 

Measuring Inflation

Page 124: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 124/133

Inflation rate

for year XCPI in year X – CPI in Year Y

CPI in year Y

X 100=

Where

CPI = consumer price index

year X = year under consideration

year Y = year immediately preceeding year X

Thus, if CPI for year X = 130; and CPI for year Y =120

Therefore

Inflation rate for year X = 130-120/12o x 100% = 8.33%

LOSERS AND GAINERS IN INFLATION

LOSERS

Page 125: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 125/133

LOSERS

1. Fixed income earners

2. Pensioners

3. Creditors

GAINERS

1. Businessmen

2. Speculators

3. Debtors

CONTROLLING INFLATION1. Monetary Policy

2. Fiscal Policy

Pharmaceutical Product Life CycleSt t i

Page 126: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 126/133

Strategies

PRODUCT LIFE CYCLE

MATURITY

DECLINE

INTRO

GROWTH

OBSOLESCENCE 

S

ALE

TIME

INCREASE

MODIFYING PRODUCT MIX STRATEGIES

Page 127: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 127/133

INCREASEUSAGE

PRESENT CUSTOMERS 

PRODUCT

MIXSTRATEGIES

NEW USERSNEW MARKET

SEGMENTS 

NEWPACKAGINGNEW FORMAT 

RE-

POSITIONINGNEW

FORMAT 

MAJOR STRATEGIES IN THE GROWTH STAGE

Page 128: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 128/133

GROWTHSTAGE

ENTERING NEW MARKETSEGMENT

EXPANDED MARKET CHANNELSINCENTIVES FOR TRADE OUTLETS

PRODUCTPOSITIONING INCREASED

LOGISTICS

SUPPORTS

LOWERING

PRICESTO PREVIOUS

LEVELS

PRODUCT

IMPROVEMENTMODIFICATION

PROMOTIONSEFFORTS

STRATEGIES IN THE MATURITY STAGE

Page 129: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 129/133

Roll back ofprices by way

of additionaldiscounts

Increasedadvertising

and otherpromotions

Increase R and Dbudgets

Periodically modifythe market, 4P’s 

STRATEGIES IN THE DECLINING STAGE

LOW MARKET PHASE OUT

Page 130: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 130/133

LOW MARKETGROWTH

LOW MARKETSHARE

LOW VOLUME

LOW PROFIT

SLOW/NON-MOVING/LESS

DEMAND

LOWPRODUCTION

HIGH COST

PRODUCTS

IN THE

DECLINING

STAGE

PHASE-OUTDISCONTINUE

REDUCEPRODUCT

OFFERINGS

REDUCE/STOPPROMOTIONSMARKETING

EFFORTS

REPLACEWEAK

PRODUCTS

FACTORS ATTRIBUTED TO SALES DECLINE

Page 131: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 131/133

1. Rapid technological advances

2. Changing consumer preferencesfor taste, flavors and colors

3. Adherence to safety andefficacy

4. Price consciousness due to

inflation and deterioratingpurchasing power

PRODUCT LIFE CYCLE CHARACTERISTICS

Page 132: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 132/133

INTRO

Low

High

Low

Negative

Negative

Few

Innovative

Very High

Very High

GROWTH

High

Very High

High

Peak Levels

Moderate

Growing

Mass market

Very High

Very High

MATURITY

Steady

Steady

Low/High

Declining

High

Many Rivals

Mass Market

Low/none

Low

1. Sales Performance

2. Market Growth

3. Market Share

4. Profit

5. Cash Flow

6. Competition

7. Customers

8. Expenses

9. ManagementSupport

DECLINE

Very Low

very Low

Very Low

Low/Zero

Low

Declining

Laggards

Very Low/N

Very Low/N

PRODUCT LIFE CYCLE RESPONSES

Page 133: 3. HECO U1 - Pharm Business Firm1

8/3/2019 3. HECO U1 - Pharm Business Firm1

http://slidepdf.com/reader/full/3-heco-u1-pharm-business-firm1 133/133

1. Strategy

2. Expenditures

3. Emphasis

4. Distribution

5. Price

6. Products

INTRO

Expand

High

Awareness

Patchy

High

Basic

GROWTH

Penetrate

High

Preference

Intensive

Lower

Improved

MATURITY

Defend

Falling

Loyalty

Intensive

Lowest

Different

DECLINE

Efficiency

Low

selective

Selective

Rising

Rationalized